Ectopic expression of the erythrocyte band 3 anion exchange protein, using a new avian retrovirus vector by Fuerstenberg, S. et al.
Vol. 64, No. 12JOURNAL OF VIROLOGY, Dec. 1990, P. 5891-5902
0022-538X/90/125891-12$02.00/0
Copyright ©) 1990, American Society for Microbiology
Ectopic Expression of the Erythrocyte Band 3 Anion Exchange
Protein, Using a New Avian Retrovirus Vector
S. FUERSTENBERG,' H. BEUG,2 M. INTRONA,3 K. KHAZAIE,4 A. MUNOZ,5 S. NESS,6 K. NORDSTROM,'
J. SAP,7 I. STANLEY,8 M. ZENKE,2 AND B. VENNSTROMl*
Department of Molecular Biology, CMB, Karolinska Institute, Box 60400, 5-10401 Stockholm, Sweden'; Research
Institute of Molecular Pathology, A-1030 Vienna, Austria2; Department of Molecular Biology "Borgomainero," Instituto
Richerche Farmacologiche "Mario Negri," I-20157 Milano, Italy3; Deutsches Krebsforchungszentrum, Institut fur
Immunologie und Genetik,4 and European Molecular Biology Laboratory, Differentiation Programme, D6900 Heidelberg,
Federal Republic of Germany; Instituto de Investigaciones Biomedicas, c/Arturo Duperier 4, E-28629 Madrid, Spain5;
Department of Chemical Immunology, Weizman Institute of Science, I-76150 Rehovot, Israel7; and Ludwig
Institute for Cancer Research, Royal Melbourne Hospital, Victoria 3050, Australia8
Received 24 April 1990/Accepted 4 September 1990
A retrovirus vector was constructed from the genome of avian erythroblastosis virus ES4. The v-erbA
sequences of avian erythroblastosis virus were replaced by those coding for neomycin phosphotransferase,
creating a gag-neo fusion protein which provides G418 resistance as a selectable marker. The v-erbB sequences
following the splice acceptor were replaced by a cloning linker allowing insertion of foreign genes. The vector
has been tested in conjunction with several helper viruses for the transmission of G418 resistance, titer,
stability, transcription, and the transduction and expression of foreign genes in both chicken embryo
fibroblasts and the QT6 quail cell line. The results show that the vector is capable of producing high titers of
Neor virus from stably integrated proviruses. These proviruses express a balanced ratio of genome length to
spliced transcripts which are efficiently translated into protein. Using the Escherichia coli j-galactosidase gene
cloned into the vector as a test construct, expression of enzyme activity could be detected in 90 to 95% of
transfected target cells and in 80 to 85% of subsequently infected cells. In addition, a cDNA encoding the avian
erythrocyte band 3 anion exchange protein has been expressed from the vector in both chicken embryo
fibroblasts and QT6 cells and appears to function as an active, plasma membrane-based anion transporter. The
ectopic expression of band 3 protein provides a visual marker for vector function in these cells.
Recombinant retroviruses have proven to be a highly
efficient means of delivering foreign genes into cultured cells
(12, 41, 42) or organisms (31, 52). The most widely used
systems employ replication defective murine leukemia virus-
based vectors and complementing packaging cell lines which
allow transcapsidation of vector RNAs into viral particles
for infecting most types of mammalian cells (9, 17, 63). In the
avian system, replication-defective retrovirus vectors have
mainly been constructed for specific experimental purposes
(18, 43, 53), though some have been adapted for general use
(6, 16). Replication-competent vectors based on Rous sar-
coma virus (RSV; 29, 55) have been constructed with the
viral src sequence replaced by a cloning site for cDNAs.
These vectors, however, have a limited cloning capacity,
making them unsuitable for the insertion of a selectable
marker plus a gene of interest. Finally, three packaging cell
lines that are based on avian leukosis virus and that provide
the functions required in trans for the encapsidation of
defective recombinant vector-derived RNAs have been re-
ported (13, 56, 60). All harbor Rous-associated virus type 1
(RAV-1) proviruses, with partial deletions in the packaging
(t,) sequences. Though other modifications to the RAV-1
genome were made, in two of these lines (56, 60) clones
which produced high titers of virus also released replication-
competent helper virus as a result of recombination. The
other packaging line (13) was created by separating helper
functions on two independent plasmids, reducing the risk of
recombinant helper virus production.
* Corresponding author.
We report here the development of a flexible avian eryth-
roblastosis virus ES4 (AEV-ES4)-based vector which con-
tains all of the sequences known to be required for packaging
of viral RNAs (11), a selectable marker (neo), and a large
cloning capacity. The vector is capable of sustained produc-
tion of high titers of recombinant virus and stable, efficient
expression of cloned sequences when transfected into
chicken embryo fibroblast (CEF) or QT6 cells. It can be used
in conjunction with several of the avian leukosis virus helper
viruses or packaging cell lines.
We have used the Escherichia coli lacZ (13-Gal) gene
cloned into the vector pSFCV to test parameters such as
transduction and expression of cloned sequences. We have
shown that the recombinant 13-Gal gene-carrying proviruses
efficiently express 1-Gal activity in up to 95% of transfected
target cells and in up to 85% of infected target cells.
In addition, a eucaryotic cDNA has been inserted to test
the vector. This cDNA encodes the chicken band 3 anion
transport protein, which catalyzes the exchange of HC03-
and Cl- at the erythrocyte plasma membrane and also
functions as an anchor for the erythroid cytoskeleton. In the
chicken, band 3 protein is encoded by two distinct polypep-
tides (30) generated by alternative initiation and splicing (34,
35). The band 3 protein transduced by our vector produces
only one of these polypeptides yet appears to function as an
active ion transporter correctly situated in the plasma mem-
brane of these cells.
MATERIALS AND METHODS
Cells and culture. CEF were prepared from 11-day-old
SPAFAS embryos (Lohmann GmbH, Cuxhaven, Federal
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FIG. 1. Schematic representation of pSFCV-neo and pSFCV-LE vectors, showing the location of rare or unique restriction sites,
nucleotide numbers (marked every 1,000 bp), locations of predicted genomic and subgenomic RNAs, location of retroviral sequences, the
gag-neo fusion protein coding sequence (G418 resistance), splice donor and acceptor sites, and cloning polylinker. (A) pSFCV-neo, a 6,883-nt
vector into which the band 3 protein coding sequence has been introduced. pSFCV-BIIIR is a 3.1-kb band 3 protein cDNA inserted into the
EcoRI site of pSFCV-neo. pSFCV-BIIIW is the same sequence cloned in the opposite orientation. The 3.3-kb p-Gal gene was cloned into
pSFCV-neo at the HindlIl site in the construct pSFCV-p. (B) Modified vector pSFCV-LE with a single 5' LTR and an 88-bp oligonucleotide
inserted between the splice acceptor and polylinker. The vector pSFCV-LE containing a 3.14-kb p-Gal insert at the Hindlll site is the plasmid
pSFCV-Blue. S.A., splice acceptor; S.D., splice donor; B, BamHI; Bg, BgIl; Bx, BstXI; C, ClaI; H, HindlIl; K, KpnI; M, BsmI; N, NotI;
P, PstI; Pv, PvuI; S, Sfil; V, EcoRV; X, XbaI. The arrows on the inserts show the location of AUG and the direction of transcription.
Republic of Germany) as previously described (23). Both
CEF and quail QT6 (44) cells were grown in Dulbecco
modified Eagle medium supplemented with 4% fetal calf
serum, 2% chicken serum, and 10mM HEPES (N-2-hydroxy-
ethylpiperazine-N'-2-ethanesulfonic acid; pH 7.3). Selection
for Neor cells was done in medium containing 0.8 mg ofG418
(Geneticin; Sigma Chemical Co.) per ml (wt/vol) for CEF
and 1.0 mglml for QT6 cells. The Q2 and Q4 packaging cell
lines were maintained as described elsewhere (60) and
otherwise treated as described for QT6 cells. The Isolde
packaging line was maintained as recommended elsewhere
(13) and otherwise treated as described for QT6 cells.
Vector construction. pSFCV-neo (Fig. 1A) was con-
structed from AEV clones 10 and 11 (14, 21, 64, 66),
representing unintegrated circular viral DNA, and inserted
into plasmid pUC19 by standard methods (40). The pUC19
polylinker was removed and replaced with NotI linkers.
AEV-derived fragments were then cloned into the plasmid
NotIl site, and the vector was constructed with the sequences
outlined in Table 1. pSFCV-LE was constructed from
pSFCV-neo by a partial BstXI digestion and religation to
create a single, fused, upstream long terminal repeat (LTR).
In addition, an 88-bp spacer sequence derived from the
human epidermal growth factor (EGF) receptor (nucleotides
[nt] 105 to 186) was inserted into the HindlIl site of the
polylinker, destroying the upstream site but retaining the
downstream site (Fig. 1B).
DNA transfection and virus production. Transfections were
performed by the method of Graham and Van der Eb as
modified by Chen and Okayama (10, 24). Vector DNA was
cotransfected with RAV-1, RAV-2, or RCAN-BHpol (28, 47,
62) helper virus DNA in a 10:1 ,ug (vector/helper) ratio.
Selection for G418-resistant (Neor) cells was initiated 48 h
after transfection by splitting the cells (1 to 3 for CEF, 1 to
10 for QT6) into G418-containing medium. Following selec-
tion of Neor cells (-6 days), cultures were maintained in
normal medium. Stable clones of Neor QT6 cells producing
virus were made by isolation and expansion of individual
colonies following G418 selection. Virus stocks were pre-
pared by withdrawal of G418 from the medium 24 h prior to
collection of cell culture supernatants from 10-cm plates.
The media supernatants were filtered through 0.45-,um-pore-
size filters (Schleicher & Schuell, Inc.) and frozen at -70°C.
The Q2, Q4, and Isolde packaging cell lines were transfected
according to the method ofGraham and Van der Eb (24), and
G418 selection and harvest of virus were done according to
the procedure described above for QT6 cells.
Virus infection and titration of virus. Cells (106) were
infected with 1 to 5 ml of culture supernatants containing 8
jig of Polybrene (Sigma) per ml for 1 to 2 h. Normal medium
was added, and the cells were grown for a further 48 h and
split into medium containing G418. The medium with G418
was changed every 2 days until selection was complete, and
the Neor cultures were expanded for preparation of RNA,
DNA, and protein. Titration of virus produced by trans-
fected or infected pools or clones of cells was done by
infection of 5 x 105 CEF or 105 QT6 cells on duplicate
60-mm dishes with 0.5 ml of serial virus dilutions in medium
containing 8 ,g of Polybrene per ml. The infections were
done at room temperature for 15 min on a rocking platform.
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TABLE 1. Location of important features in pSFCV-neo"
Nucleotide no. Siteb Source (reference)
6683 Former EcoRI site of pUC19
1-8 Notl linker
9 Beginning of AEV sequences pAEV-11 (18, 59)
643-1320 5' double LTR pAEV-11 (18, 59)
982-983 Circle junction pAEV-11 (18, 59)
983-1210 5' U3 (promoter) pAEV-11 (18, 59)
1220-1240 R pAEV-11 (18, 59)
1241-1320 5' U5 pAEV-11 (18, 59)
1220 Cap site pAEV-11 (18, 59)
1321-1335 tRNA primer binding site. pAEV-11 (18, 59)
1597 gag-neo initiation codon pAEV-11 (18, 59)
1597-2243 gag coding sequence pAEV-11 (18, 59)
2244-2285 Synthetic oligo
2251-3043 neo coding sequence TnS
1614 Splice donor site pAEV-11
3043-3291 erbB intron pAEV-11
3291 Splice acceptor site (v-erbB) pAEV-11
3302-3370 Cloning polylinker Synthetic oligo
3320 Stop codon (spliced mRNA) Synthetic oligo
3303-3356 Cloning sites Synthetic oligo
3357, 3362, 3366 Stop codons (all frames) Synthetic oligo
3369-3603 AEV env (noncoding) pAEV-10 (18, 59)
3604-3896 AEV 3' noncoding region pAEV-10 (18, 59)
3897-4135 3' U3 pAEV-10 (18, 59)
4135-4155 R pAEV-10 (18, 59)
4156-4235 3' U5 pAEV-10 (18, 59)
4129-4134 Polyadenylation signal pAEV-10 (18, 59)
4156 Polyadenylation site pAEV-10 (18, 59)
4242 End of AEV sequence pAEV-10 (18, 59)
4243-4251 NotI linker
4252 Former HindIll site of pUC19
a Details of the construction and compiled sequence of pSFCV-neo can be
obtained upon request over computer network (BVE@Kitomo.KI.SE) or by
sending an address-labeled Macintosh-formatted diskette. Sequences derived
from AEV-ES4 are present at nt 1 to 4242 and make up the retroviral segment,
including the bacterial neomycin phosphotransferase gene and a 68-bp syn-
thetic cloning linker following the splice acceptor. All cloned sequences are
intended to be expressed from the spliced subgenomic transcript, must supply
their own AUG, and are cloned in the same orientation as viral sequences.
The selective marker, G418 resistance, is provided by a gag-neo fusion
protein. A synthetic linker joins the two reading frames to create the
p55gag-e'n hybrid protein. Nt 4243 to 6683 represent the pUC19 plasmid
backbone. In pSFCV-LE, modifications which leave a single 5' LTR and
extend the distance from the splice acceptor to the cloning linker have been
introduced.
b U3, U5, R, Unique 3', 5', and repeated sequences of the LTR, respec-
tively; env, retroviral envelope gene.
Five milliliters of normal medium was then added, and the
cells were returned to the incubator. The cells were washed
and refed with fresh medium 24 h later and refed with
medium containing G418 48 h after the time of infection.
Thereafter, the selective medium was changed every day
until easily visible Neor colonies appeared (-12 days), at
which time the cells were fixed in methanol-acetone (2:1) and
stained with gentian violet to count colonies. Only colonies
of average size or larger were counted as resulting from the
initial virus infection; they were used to calculate titers as
infectious Neor units per milliliter.
Supernatants from the Q2 and Q4 packaging lines were
assayed for titer on QT6 cells as described above. Virus
production by Isolde lines were similarly assayed for titer on
CEF cells or by dot blot (see below). To test for the
production of replication-competent recombinant helper vi-
rus, fresh QT6 cells were infected with culture supernatants
from SFCV-neo-transfected Q2 or Q4 cells, or CEF cells
were infected with culture supernatants from SFCV-Blue-
transfected Isolde cells and then selected for outgrowth of
G418-resistant colonies. The G418 was withdrawn from the
medium, and the culture supernatants were once again
harvested to infect fresh QT6 or CEF cells, which were
selected on G418 for outgrowth of resistant colonies. Any
Neor colonies appearing in this final infection were assumed
to be due to recombination of the input SFCV-neo or
SFCV-Blue vector sequences with the resident RAV-1 ge-
nome of the Q2, Q4, or Isolde packaging line.
Estimation of virus titer by using RNA dot blot. Virus titers
from cells harboring SFCV-Blue constructs were estimated
by dot blot hybridization. Virus was pelleted from superna-
tants of SFCV-Blue-transfected Isolde clones or from helper
virus-cotransfected CEF pools and used to prepare RNA for
dot blotting as previously described (33). Serial threefold
dilutions of RNA were applied to nitrocellulose by using a
dot blot manifold (40) and hybridized by using a 32P-labeled
910-bp neo probe. Conventionally assayed SFCV-Blue su-
pernatants (see Virus infection and titration of virus above)
were used as controls for comparative estimation of virus
titers by scanning the autoradiograph with an integrating
laser densitometer. These values were converted to esti-
mated virus titer, expressed as unitse per ml (see Table 3).
Southern and Northern (RNA) analyses. Genomic DNA
was prepared from 10-cm plates of confluent cells, digested
with BstXI or BgIII, subjected to electrophoresis on 0.8%
agarose gels, and transferred to nylon membranes (Hybond
N; Amersham Corp.). Southern blots were probed with a
32P-labeled neo fragment prepared by random hexamer
labeling (19) (Multiprime Labeling System; Amersham).
Poly(A)+ RNA for Northern analysis was prepared as pre-
viously described (65) from 15-cm plates of semiconfluent
cells. Poly(A)+ RNA (1 to 2 ,ug) was electrophoretically
separated on 1% agarose-formaldehyde gels containing
MOPS (morpholinepropanesulfonic acid, pH 7.0) at 140 V
for 4 to 5 h. The RNA was transferred to membranes and
hybridized with 32P-labeled neo, env, or chicken band 3
protein fragments derived from pSFCV-BIIIR.
P-Gal assays. In situ assays for n-Gal production were
performed on glutaraldehyde-fixed subconfluent plates of
SFCV-Blue-transfected or infected CEF or Isolde cells
according to a protocol described by Dannenberg (15, 50).
Blue colonies were counted after 6 to 10 h. To determine the
percentage of colonies expressing P-Gal, these plates were
rinsed in phosphate-buffered saline, treated with acetone-
methanol, and stained with gentian violet to assess the total
number of Neor colonies. Only blue colonies of uniform size
(P-Gal) were scored.
Protein analyses. Immunoprecipitation of 35S-labeled cell
extracts with gag and band 3 protein antibodies was done as
previously described (3), using protein A-Sepharose (Phar-
macia) and monoclonal antibodies MCA2E (67) to chicken
band 3 protein, MC4.2.A5 (25) to chicken hemoglobin, and
M3CZC (26) to viral gag (p19) polypeptides. Labeled extract
(107 cpm) was used for each immunoprecipitation.
For immunofluorescence studies, fibroblasts were de-
tached from the culture plastic with EDTA and fixed in
paraformaldehyde. Anti-chicken band 3 protein monoclonal
antibody coupled to fluoroscein isothiocyanate-goat anti-
mouse immunoglobulin was used to visualize the location of
the band 3 protein, as described elsewhere (68).
Assay for anion transporter function. Anion transporter
activity was tested in two ways. First, SFCV-BIIIR- and
SFCV-BIIIW-infected (Neo) cells were cultured for 24 h in
the presence or absence of 0.4 mM DIDS (diisothiocyanodi-
hydrostilbene-2.2' disulfonic acid; Sigma), a specific inhibi-
tor of band 3 protein activity. The presence of vacuoles was
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monitored under a phase-contrast microscope. Second, cells
infected with SFCV-BIIIR or SFCV-BIIIW were grown in
parallel in normal media adjusted to pH 7.2 or 8.0 by the
addition of bicarbonate and allowed to grow for 48 h. The
presence of vacuoles was monitored under the microscope.
RESULTS
Strategy for pSFCV-neo vector construction. We chose the
AEV-ES4 genome as the basis for the construction of
pSFCV-neo, since the AEV LTRs are active in many types
of avian cells, including fibroblasts, erythroblasts, myelo-
blasts, and blastoderm cells (4, 20, 22). Also, the virus is
efficiently packaged when pseudotyped with a variety of
helper viruses, yielding titers of 105 to 106 infectious parti-
cles per ml (20, 22). In pSFCV-neo, the LTRs and gag
sequences originate from the cloned AEV genome (66; Fig.
1). Because packaging sequences, a splice donor site, and
other functions (11) are in part located in the gag regions of
avian sarcoma and leukosis viruses, we chose to retain 646
nucleotides of gag coding sequence (NaeI site). To be able
to accommodate a selectable marker (Neor) as well as one or
several additional genes in the vector genome, we fused the
necessary parts of gag in frame with the bacterial neomycin
phosphotransferase gene (neo). In this way, transcription,
packaging, and selectable marker functions were confined to
a minimal genetic unit. The gag-neo hybrid protein has an
estimated molecular size of 53,000 daltons and is expressed
from genome-length RNA at easily detectable levels.
The Neor gene is followed in pSFCV-neo by a short
intervening sequence and a splice acceptor site, both derived
from AEV. In spliced subgenomic RNAs from avian retro-
viruses, the splice donor site is preceded by the six initial
codons of gag. To allow the expression of unmodified
proteins from subgenomic mRNAs, we inserted after the
splice acceptor site a polylinker containing a terminator
codon in frame with the upstream AUG. Consequently,
cloned sequences had to supply their own start codon. The
restriction sites in the polylinker are followed by stop codons
in all three reading frames, and mRNAs utilize polyadenyl-
ation signals in the 3' LTR. The Hindlll site at the start of
the polylinker and the EcoRI site at the end facilitate the
insertion of genes from pUC vectors. The ClaI site in the
SFCV-neo polylinker allows the insertion of an additional
gene by the use of adaptor plasmids (28), which carry their
own splice acceptor site, initiator AUG, and cloning poly-
linker. All polylinker sites except that for BglI, which is also
present in the plasmid vector, are unique in pSFCV-neo. The
BstXI sites in the LTRs are unique and can be used to excise
the integrated provirus. NotI linkers separate SFCV se-
quences from the pUC backbone in the plasmid pSFCV-neo.
The genomic transcript has a calculated length of 2,963 nt,
and the spliced mRNA is 1,250 nt, excluding the insert and
poly(A) tail. The estimated cloning capacity based on RSV-
derived vectors (48, 58) is greater than 6.5 kb.
pSFCV-BIIIR (band 3, Fig. 1A) represents the vector
pSFCV-neo containing an EcoRI insert of 3.1 kb containing
the cDNA for the avian erythrocyte band 3 protein (68) in the
same orientation as the viral sequences. The insert harbors
its own ATG initiating codon and stop codons. This partic-
ular construct was designed to express band 3 protein as a
spliced viral transcript via the promoter and polyadenylation
site in the retroviral LTRs. pSFCV-BIIIW contains the same
EcoRI fragment in the opposite orientation.
pSFCV-3 (a-gal, Fig. 1A) contains 3.3 kb of bacterial
1-Gal sequence cloned at the HindIlI site of the SFCV-neo
polylinker. The expression of the spliced ,B-Gal mRNA from
SFCV-1 was easily detectable by Northern analysis (data
not shown), but transfected cells scored weakly or unevenly
positive when in situ assays were used to determine 1-Gal
activity. Since the construct produced only weak enzyme
activity, it was used for quantitation of virus production and
Southern blot analysis only.
pSFCV-LE (Fig. 1B) was constructed from pSFCV-neo
by partial BstXI digestion and religation to create a single
upstream LTR. In addition, a modification was made to
ensure the efficient translation of inserted sequences. In
pSFCV-neo, the presence of a stop codon following the
splice acceptor prevents the fusion of gag sequences to
cloned genes. To provide a proper distance (37) between this
stop codon and the AUG of cloned sequences, we inserted a
synthetic 88-bp fragment representing a modified form of the
human EGF receptor 5' untranslated region (nt 105 to 186)
into the Hindlll site of the pSFCV-neo polylinker. This
version of the vector efficiently allowed production of 1-Gal
(assayed in situ for enzyme activity) as a Hindlll insert in
pSFCV-LE.
pSFCV-Blue (a-gal, Fig. 1B) represents a 3.14-kb E. coli
13-Gal (50) fragment cloned into the Hindlll site of
pSFCV-LE in the same orientation as viral sequences. This
construct was used for in situ quantitation of ,B-Gal activity
and virus production (Tables 2 and 3).
Expression of neomycin resistance by SFCV-neo. To test
the ability of SFCV-derived gag-neo hybrid protein to pro-
vide G418 resistance to CEF and QT6 cells, pSFCV-neo was
compared with the plasmid pSV2neo (45) in parallel trans-
fections. Equal amounts of plasmids were transfected onto
CEF cells, and the resulting sizes and numbers of Neor
colonies were noted. pSFCV-neo gave between 50 and 70,
pSFCV-1 gave 80 to 100, and pSFCV-Blue gave 90 to 100
Neor colonies per ,ug of DNA, comparable with that ob-
served using pSV2neo (25 to 30 Neor colonies per jig) at 0.8
mg of G418 per ml. At G418 concentrations of 2.0 mg/ml, all
plasmids gave 10 to 15 Neor colonies per jig of DNA. The
size of the Neor colonies from SFCV transfectants were
comparable with those of pSV2neo transfectants.
Virus production by pSFCV-neo-helper-transfected cells.
To estimate the amount of virus released by cells harboring
the SFCV-neo provirus, constructs were cotransfected into
CEF or QT6 cells with several helper virus DNAs such as
RAV-1, RAV-2, and RCAN-BHpol. RCAN-BHpol is a
construct based on RSV-Schmidt-Ruppin A, which lacks
v-src, contains the pol region of the Bryan high-titer strain
(RSV), and was designed to produce higher titers of virus
(28, 47, 62). Culture supernatants were harvested from pools
of CEF cells or clones of QT6 cells at different times after
transfection, and titers were then determined on equivalent
populations of CEF or QT6 cells. The titrations were judged
by the outgrowth of G418-resistant colonies and expressed
as infectious Neor units per milliliter of culture supernatant.
The production of recombinant virus was greater than 105
Neor units per ml by all Neor_selected groups of cells,
regardless of the cell type, helper virus, or SFCV provirus
present, with the exception of RAV-1 transfectants (Table
2). In general, RAV-1-transfected cells produced lower
levels of virus with any SFCV construct than did RAV-2- or
RCAN-BHpol-transfected cells. In addition, virus produc-
tion by QT6 cells (clones) tended to be more uneven than
that by CEF (pools), which was not unexpected. The results
also show that relatively high virus production (1 x 104 to 2
x 104 Neor units per ml) can be detected in unselected cells
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TABLE 2. Production of recombinant virus
Titer (Neor units/ml)'
Provirus Cell type Helper 48 h G418 selected
SFCV-neo CEF RAV-1 <1 x 103 4 x 106
RAV-2 ND 1 X 106
RCAN-BHpol 2 x 104 5 X 106
QT6 RAV-1 >1 X 103 1 X 105
RAV-2 >1 x 103 1 X 106_8 X 106
RCAN-BHpol 1 X 104 5 x 106
SFCV-, QT6 RAV-1 <1 x 103 <1 X 103
RCAN-BHpol 1 X 104 1 X 106-10 X 106
SFCV-BIIIR CEF RCAN-BHpol ND 1 x 106- 8 x 106
SFCV-BIIIW CEF RCAN-BHpol ND 2 x 105-10 X 105
SFCV-Blueb CEF RCAN-BHpol ND 2 x 106- 4 x 106c
a Titers of less than 103 were not scored. ND, Not done. Results are tabulated from several pSFCV variants and helper viruses. CEF titers are taken from pools
of cells, and QT6 titers are averages of individual clones.
b Includes the percentage of cells scoring positive in situ a-Gal assays.
' Of neor colonies, >89% were P-Gal positive.
harboring pSFCV-neo and RCAN-BHpol as early as 48 h
posttransfection.
The production of virus by the SFCV-neo-transfected
packaging lines Q2 and Q4 (Table 3) was lower than that by
helper-cotransfected cells, which was expected. Half of the
Q2 transfectants produced titers of between 102 and 103
infectious Neor units per ml, while the other half produced
virus at levels too low to detect (<20 Neor units per ml). The
Q4 packaging line produced consistently higher titers of
around 2 x 104 Neor units per ml, though again from only
half of the clones selected. No recombinant helper virus was
detected from any of the clones when the techniques de-
scribed in Materials and Methods were used. However,
when SFCV-neo-transfected Q2 or Q4 cells were maintained
as uncloned pools of G418-resistant cells, even for short
periods, recombinant helper could be detected in the me-
dium of QT6 cells infected with culture supernatants from
those pools. This meant that recombination of SFCV-neo
with the resident RAV-1 genome of Q2 or Q4 cells was
frequent enough to detect in any transfection but could be
avoided by selection of individual clones of virus-producing
cells.
Production of virus by pSFCV-Blue-transfected Isolde
packaging cell pools or clones was consistently between 1 x
104 and 5 x 104 Neor unitse per ml of cell culture supernatant
(Table 3). This was equal to those values observed with
packaging line Q4. However, unlike the situation with Q2 or
Q4 transfectants, the presence of recombinant helper virus
could not be detected (see Materials and Methods) in cloned
or uncloned pools of Isolde transfectants. Of 22 Neor clones
tested, all scored positive for 3-Gal production, with 18
clones at least 90% ,B-Gal positive. When assayed for virus
production by dot blot, these 18 cloned lines all produced
about 104 virus units per ml (Table 3). A total of 80 to 85% of
cells infected with these Isolde supernatants also scored
positive by in situ ,-Gal assays.
Integration and maintenance of SFCV-neo provirus. To
examine the status of the SFCV provirus, virus supernatants
were used to infect CEF or QT6 cells, and Neor pools (CEF)
or clones (QT6) of cells were isolated and expanded for
Southern analysis. BstXI, which cuts in the retroviral LTRs,
and BglII, which cuts once in SFCV, were used to determine
integration sites and copy number, respectively, of the
SFCV provirus in infected cells. The SFCV-neo provirus
was integrated and stably maintained at one to three copies
per cell in all cell populations (Fig. 2). The probe used for
this purpose was a 910-bp neo fragment. In some lanes
(SFCV-P*), 10 pg (-1 copy equivalent) of pSFCV-neo
plasmid DNA was included in the restriction digests for
comparison. The first lane contains BstXI-cleaved pSFCV-
neo DNA alone.
Expression of P-Gal activity by pSFCV-Il and pSFCV-Blue.
Transfected Neor populations of CEF cells expressing
SFCV-P were assayed in situ for P-Gal activity. In general,
1 to 10% of the cells expressed enzyme activity, and clones
of cells remained uneven, with a fraction losing or gaining
TABLE 3. Virus titers for transfected cell linesa
PackaginglineTransfecting Celclones'. Titer' Presence 3-Gal positivePackagin ine agent l of helper ()
Q2 SFCV-neo 1-4 7 x 1014 X 102
5-10 <1 x 101
Pool 2 x 102 +
Q4 SFCV-neo 1-5 2 x 104-5 X 104
6-10 <1 x101-
Pool 3 x 104 +
Isolde SFCV-Blue 1-18 2 x 104-5 X 104d - >90
19-22 1 X 103-5 X 103d 20-50
Pool 1 X 104d _ >90
a Packaging cells were transfected with DNA from pSFCV variants, and individual Neor clones were isolated and assayed for titer. The clones are grouped
according to relative titers.
b Pools were of uncloned Neor cells.
Titers of less than 2 x 10' were not scored in this assay.
d Estimated virus titer from dot blot assays expressed as Neor unitse per milliliter.
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FIG. 2. Southern blot of SFCV provirus in SFCV-neo- or SFCV-BIlIR-infected QT6 or CEF cells. High-molecular-weight DNA (10 ,ug)
from infected cells was cleaved with BgllI (lanes B) to analyze integration sites or with BstXI (lanes X) to determine copy number of
proviruses. SFCV-neo, DNA from SFCV-neo-infected pools of CEF cells (pools 1 to 3) or isolated clones of QT6 cells (clones 1 to 3);
SFCV-BIIIR, DNA from SFCV-BIIIR-infected pools of CEF cells (pools 1 and 2) or isolated clones of QT6 cells (clones 1 and 2); SFCV-P*,
DNA from SFCV-13-infected pools of CEF cells (pool 1) or clones of QT6 cells (clones 1 and 2) along with 10 pg (-1 copy equivalent) of
pSFCV-neo DNA as an internal control for comparison. The asterisks represent the migration of the pSFCV-neo internal plasmid controls
in SFCV-,P* lanes. Numbers on the right indicate the sizes of fragments of the StyI-cleaved A DNA marker. The first lane in panel SFCV-neo
contains a pSFCV-neo plasmid control. The probe used for this purpose was a 32P-labeled 910-bp neo fragment.
expression as the cells were passaged for short periods. In an
attempt to remedy the failure of pSFCV-1 to efficiently
express 13-Gal activity, the vector was modified as described
above. The new version, pSFCV-Blue, was then assayed in
two sets of experiments for its ability to transduce 1-Gal
activity to transfected or infected cells (Tables 2 and 3). CEF
or Isolde cells were transfected with pSFCV-Blue and plated
sparsely enough to distinguish individual colonies following
G418 selection. These were assayed in situ for 1-Gal pro-
duction and later stained with gentian violet to count all Neor
colonies. In two separate transfections, 106 of 117 (90%) and
50 of 56 (89%) of Neor CEF colonies were positive for 13-Gal
activity. Of 22 isolated Isolde clones, all were positive for
13-Gal activity, with 18 clones being >90% positive. To
assess the ability of SFCV-Blue viruses to transduce 13-Gal
activity, supernatants of the 18 transfected Isolde cell clones
were used to infect fresh CEF cells. Of the clones tested, all
infected CEF pools scored positive by in situ staining. About
90% of the infected cells in any pool were 1-Gal positive.
When these CEF infectants are grown sparsely to isolate
colonies, >80% of the Neor colonies were 13-Gal positive,
depending on the virus stock. These results are in stark
contrast to the weak 1-Gal activity transduced by our
previous construct, pSFCV-1.
Expression of RNAs from SFCV-neo LTR. Northern anal-
ysis of SFCV-neo-infected CEF or QT6 cells was used to
determine the relative amounts of SFCV genomic and
spliced RNAs present in infected cells. A neo probe detected
the full-length genomic RNA in the SFCV-neo- and SFCV-
BIIIR-infected cells (Fig. 3). An env-specific probe detected
all RNAs of vector and helper virus origin. Cells containing
SFCV-neo proviruses without inserts produced the 3.0-kb
full-length SFCV-neo transcript, but they all failed to pro-
duce the expected spliced transcript of 1.25 kb. Instead, a
2-kb cryptically spliced RNA was observed. In cells harbor-
ing SFCV proviruses containing foreign sequences (Fig. 3,
band 3), the relative amount of this cryptically spliced RNA
was lower than in SFCV-neo-infected cells, but an additional
cryptically spliced mRNA was seen at 1.8 kb. In cells
harboring the SFCV-BIIIR construct, the probe for band 3
detected mainly the 6.1-kb full-length RNA, the 4.35-kb
spliced subgenomic RNA, and the cryptic 1.8-kb RNA. The
SFCV-neo 2-kb cryptic splice could result from the utiliza-
tion of a potential cryptic acceptor site created at the
gag-neo junction. The 1.8-kb cryptic splice could result from
splicing within the band 3 protein coding sequences. The
presence of these alternatively spliced mRNAs did not seem
to interfere with the production of sufficient neo to provide
G418 resistance or the production of band 3 protein from the
correctly spliced mRNA. Experiments to determine the
origin of these cryptic splice points are currently under way
as part of an attempt to eliminate the points from the SFCV
constructs.
Expression of SFCV gag-neo protein. Immunoprecipitation
of gag-related proteins from SFCV-BIII-infected cells (Fig.
4) showed two specific products. The pr769ag protein repre-
sents the precursor gag protein expressed by the helper
virus, whereas the smaller gag polypeptide is the vector-
derived gag-neo fusion protein of 55,000 Mr. The observed
size of the p55gagneo protein is in agreement with the
estimated size of a 482-amino-acid gag-neo fusion protein of
53,000 daltons. Though the amount of p55gag-neo protein was
low compared with that of pr76gag of the helper virus, it was
sufficient to provide Neor, even at concentrations of 3 mg of
G418 per ml, which is necessary for the selection of eryth-
roblast cultures (data not shown).
Band 3 protein expression from SFCV in fibroblasts. The
cDNA encoding chicken erythrocyte band 3 protein was
successfully expressed in fibroblasts using the pSFCV-neo
vector. Immunoprecipitation of band 3 protein (Fig. 4) in
CEF cells transfected with SFCV-BIIIR and RCAN-BHpol
showed a strong band in the 95-kDa molecular size range
which is absent from SFCV-BIIIW (opposite orientation)-
transfected cells and similar to the band for the native
protein immunoprecipitated from EGF receptor-transformed
erythroblasts (33). This size is in agreement with the estab-
lished molecular weights of erythrocyte band 3 polypeptides
of 100,000 and 105,000 (doublet). The cDNA used to express
band 3 protein in the SFCV-BIIIR construct represents only
one of these two polypeptides, which are generated by
alternative initiation and splicing of mRNAs (34, 35).
Indirect immunofluorescence of CEF expressing the
SFCV-BIII constructs (Fig. SA) using a band 3-specific
monoclonal antibody showed a bright ring of fluorescence
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FIG. 3. Northern blot of RNAs expressed from SFCV proviruses in SFCV-neo- and SFCV-BIIIR-infected cells. Poly(A)+ RNA (2 ,ug)
from SFCV-neo-infected QT6 cell clones (cl.), an SFCV-BIIIR-infected QT6 cell clone, or helper virus-infected QT6 cells was analyzed with
a battery of probes. An env probe was used to detect all viral transcripts, a neo probe was used to detect SFCV-specific transcripts, or a
chicken band 3 probe was used to detect band 3 transcripts. The marker (lane M) was an end-labeled HindIII-EcoRI digest of DNA. The
arrows on the left indicate the migration of the various RNAs: helper virus genomic and subgenomic transcripts, 7.8 and 2.7 kb;
SFCV-neo-derived genomic RNA, 3.0 kb; cryptically spliced RNA, 2.0 kb; band 3 protein-derived genomic RNA, 6.1 kb; subgenomic RNA,
4.4 kb; cryptically spliced RNAs, 4.6 and 1.8 kb. Lane SFCV-BIIIR* represents a shorter exposure of the SFCV-BIIIR lane to its left. The
32P-labeled probes used for this purpose were a 580-bp env fragment, a 910-bp neo fragment, and a 3.0-kb band 3 protein fragment, all derived
from SFCV-BIIIR.
located at the periphery of cells transfected with SFCV-
BIIIR DNA and absent in SFCV-BIIIW counterparts. This
is consistent with the plasma membrane localization of band
3 protein in erythrocytes and shows that the vector-encoded
protein behaves in a manner consistent with its role in vivo.
All Neor clones or pools of band 3 protein-transfected or
infected cells thus far analyzed have produced band 3
protein by one or more of the three criteria we use, i.e.,
immunoprecipitation, immunofluorescence, or vacuoliza-
tion.
CEFs infected with SFCV-BIIIR, but not SFCV-BIIIW,
viruses become highly vacuolated. In order to assess
whether this was due to the ion exchange activity of the
ectopically expressed band 3 protein, two experiments were
performed. The first was to alter the bicarbonate content of
the cell culture medium, which can be used to modulate
anion transport activity. After 48 h in normal pH 7.2 me-
dium, the vacuoles remained (Fig. 5B), but when the same
cells were grown in pH 8.0 medium in a parallel experiment,
the vacuoles disappeared. There was no change in SCFV-
BIIIW-transfected cells under the same conditions. All cells
grew normally at both pH values.
Second, we used the compound DIDS (a stilbene disul-
fonate derivative), which functions as an inhibitor of band 3
protein by irreversibly binding to the extracellular domain of
the protein and blocking anion transport. The addition of 0.4
mM DIDS to the cell culture medium caused, within 24 h,
the elimination of vacuoles from SFCV-BIIIR-transfected
cells while having no apparent effect on their growth (Fig.
5C). There was no effect on SFCV-BIIIW-transfected cells
under the same conditions (data not shown). These results
also indicated that the ectopically expressed band 3 protein
was located in the plasma membrane in the correct orienta-
tion and mediated anion transport, as does the endogenous
erythrocyte protein. Each cell expressing the band 3 protein
SFCV
BIIIR
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FIG. 4. Immunoprecipitation of p19 gag-related polypeptides or
band 3 proteins from SFCV-BIIIR-infected cells. 35S-labeled pro-
teins from infected cells were immunoprecipitated with anti-band 3
protein (lane 1) or anti-p199'9 (lane 2) antibodies. The proteins were
prepared from SFCV-BIIIR (left)- or SFCV-BIIIW (center)-infected
CEF cells. The right-hand panel contains these proteins immuno-
precipitated from human EGF receptor-transformed erythroblasts
(EGFR-ebl). Arrows at the extreme right correspond to the antici-
pated migration of band 3- and p199a9-related proteins; pr76 gag,
helper virus gag protein precursor; p55 gag-neo, gag-neo fusion
protein encoded by SFCV-neo. The vertical bars to the left of lanes
1 represent the anticipated migration of band 3 polypeptides. The
arrows to the right of lanes 2 indicate the anticipated migration of
gag proteins. Numbers on the left correspond to the migration of
molecular size standards in kilodaltons.
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FIG. 5. (A) Band 3 protein-specific immunofluorescence of intact CEF cells containing SFCV-Blll proviruses. Indirect immunofluores-
cence of CEF cells expressing SFCV-BIIIR and SFCV-BIIIW proviruses. The left half of the panel shows cells stained for expression of band
3 protein, and the insert shows an enlargement of the same cells. The right half of the panel shows the same cells stained with antibodies to
hemoglobin (Hb; negative control). Notice the intense peripheral staining of SFCV-BI1IR cells when the band 3 protein antibody is used
(arrows). (B) Effect of pH on the vacuolization of SFCV-BIIIR-containing fibroblasts. The left half of the panel shows CEF cells grown for
48 h at the normal pH of 7.2. The right half of the panel shows the same pool of cells grown for 48 h in pH 8.0 medium. Notice the multiple,
large vacuoles in SFCV-BIII-containing cells at the normal pH. (C) Effect of DIDS on band 3 protein-expressing fibroblasts. CEF cells
harboring SFCV-BIIIR proviruses were cultivated for 24 h at pH 7.2 in medium containing DIDS (right) (see Materials and Methods), an
inhibitor ofband 3 protein ion exchange function. The figure on the left shows the same cells under normal conditions (pH 7.2, no DIDS).
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acquired vacuoles, which served as an excellent visual
marker for vector function in this cell type.
DISCUSSION
The SFCV-neo vector was adapted from AEV-ES4 with
the object of retaining several features important for viral
replication, such as the high activity of the viral LTRs in
many types of avian cells and the ability of AEV to produce
large amounts of virus with functions provided in trans by
several different helper viruses. The LTRs contained the
viral promoter, cap site, polyadenylation signals, proviral
integration sites, and one of the important enhancer se-
quences, located in the R-U3 region (38, 54). In addition,
several cis-acting elements outside of the viral LTRs were
also retained, as discussed below.
Packaging sequences (4I) of the avian retroviruses are
found at several points on the viral genomic RNA. An
important * sequence lies in the untranslated leader region
between U5 and the start of gag (32). This -30-bp sequence
is located -250 bp from the 5' end of the genomic RNA and
constitutes a major part of the sequences required for
efficient encapsidation of viral RNAs; it overlaps in part with
sequences affecting viral replication and protein translation
(5, 46, 49). In addition, another important packaging signal
lies within the structural gene for gag (51), about 150 bp
downstream of the splice donor site. Also, some of the
sequences directly involved in the genome dimerization step
necessary for encapsidation are located in this region (5).
Finally, noncoding sequences 3' of env are thought to be
involved in viral genome assembly (27, 58) for packaging.
SFCV-neo was designed to encompass all of the sequences
mentioned above.
In the avian sarcoma and leukosis viruses, other cis-acting
sequences overlap the gag coding sequences, and they are
retained in SFCV-neo. These sequences affect splicing (39,
57, 61), contain determinants of viral tropism (53), and also
make up a second important enhancer region (1, 8, 61).
Recent studies using in vitro chloramphenicol acetyltrans-
ferase assays show that a series of deletions in gag, extend-
ing from the 3' end, result in a continual reduction in
transcriptional activity compared with that of the intact
sequence (1). In mutations extending beyond a critical
region, transcription is markedly reduced. This enhancer
region, required for efficient viral transcription in some cell
types (1, 61), is located just upstream of the gag-neo junction
in pSFCV-neo (nt 2243).
To avoid promoter interference by competing transcrip-
tional regulatory domains (18), we chose to express inserted
sequences from spliced, subgenomic RNAs in SFCV-neo.
RSV efficiently utilizes multiple splice acceptors in this
context (env and src). The splice donor site in SFCV is
located after the sixth codon in gag, and the splice acceptor
site is that of the v-erbB gene, both derived from AEV. In
the context of SFCV, these sequences functioned efficiently
to direct the splicing of subgenomic mRNAs when cloned
inserts were present in the SFCV-neo polylinker. In the
absence of cloned sequences, the expected subgenomic
mRNA could not be detected, and cryptically spliced RNAs
were present in all SFCV-neo variants. These cryptic splices
probably result from the introduction of foreign sequences,
such as neo, into the retroviral genome and do not seem to
interfere with splicing or translation of the correct mRNAs in
pSFCV-transfected or infected cells. Cryptic splicing has
also been noted in murine retrovirus vectors (7; personal
communication); the aberrant splicing seems to have no
effect on expression of correctly spliced RNAs. However,
experiments are currently under way to determine the sites
of these aberrant splice points and remove them from
pSFCV.
The SFCV polylinker is immediately downstream of the
SFCV splice acceptor and contains first a stop codon,
closing the reading frame initiated in the RNA leader; then
restriction sites for HindIll, EcoRV, BglI, SfiI, ClaI, XbaI,
and EcoRI; and then stop codons in all frames. By using
adaptor plasmids which carry the RSV src splice acceptor,
leader sequence, and an adjoining polylinker on a ClaI
fragment (25), a second spliced mRNA could potentially be
produced by SFCV-neo proviruses.
In pSFCV-LE, a further modification has been made in the
region near the splice acceptor. We have inserted a modified,
synthetic 88-bp human EGF receptor fragment (nt 105 to
186) to provide a spacer between the stop codon and the
beginning of the polylinker. This sequence, in an unmodified
form, has been previously used by our lab to produce about
106 EGF receptor molecules per cell from an AEV vector in
a similar context (33). It has been shown that a minimum
sequence is required between a stop codon and an in-frame
AUG to allow efficient ribosomal reinitiation (37). The
original SFCV-P-Gal construct (SFCV-p) was a 3.3-kb frag-
ment cloned into the first (HindIII) site of the polylinker.
SFCV-1 produced weak, erratic p-Gal activity in transfected
and infected cells, although 3-Gal-specific subgenomic RNA
was abundant in these cells (data not shown). However,
when the P-Gal gene was cloned into the Hindlll site of the
C normal
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modified SFCV-LE vector, enzyme activity was detected in
>90% of Neor transfected cells even after several genera-
tions in culture.
The potential cloning capacity of SFCV-neo can be esti-
mated from RSV. This virus encodes a 9.3-kb genomic
RNA, and infectious mutants with a genome length of up to
10.1 kb exist (48). This would allow, by analogy, cloning of
between 6.4 and 7 kb of foreign sequence into SFCV-neo
without impairing the efficiency of packaging. Experiments
to test this are currently under way: two genes expressed
from separate splice acceptors will be inserted into pSFCV-
LE. The total insert size will be 6.5 kb.
The fusion of gag to neo in SFCV-neo did not affect the
ability of the neomycin phosphotransferase protein to pro-
vide Neor in the presence of high concentrations of G418,
and the cis- and trans-acting activities present in gag ap-
peared to be undisturbed. Consequently, all of the important
regulatory signals encoding splicing, enhancer, and se-
quences were retained in the gag region, while the neo
portion efficiently provided G418 resistance to infected cells,
as shown by titration experiments. In SFCV-neo, both the
unspliced and the spliced mRNAs were efficiently translated
into protein, as shown by immunoprecipitation of the gag-
neo and band 3 proteins.
We have used the E. coli lacZ (a-Gal) gene to test the
features of vector function. Using two separate 13-Gal con-
structs, we have tested expression of ,8-Gal protein by in situ
analysis and analyzed virus titers from SFCV-1-gal-trans-
fected cells. Using the SFCV-Blue construct in transfection
experiments with both QT6 and CEF cells, we have shown
that enzyme activity is efficiently expressed in >90% of
G418-selected clones or pools of cells. When supernatants
from three of these cell clones were used to infect CEF cells,
>80% of colonies were ,8-Gal positive Neor. SFCV-Blue has
also been used to express 13-Gal in erythroblasts (data not
shown), and >95% of the infected Neor erythroblasts ex-
pressed enzyme activity by in situ analysis. SFCV-,-
RCAN-BHpol-cotransfected QT6 cells efficiently produced
106 Neor units per ml of virus, and SFCV-Blue-RCAN-
BHpol-cotransfected CEF cells yielded similar titers of 2 x
106 to 4 x 106 Neor units per ml.
We chose the cDNA for the erythrocyte anion transporter
to analyze the expression of a eucaryotic gene from the
SFCV-neo vector. We are also interested in the role of band
3 protein repression by v-erbA in the AEV transformation of
erythroblasts (68). The SFCV viruses are intended for use in
erythroblasts as well as fibroblasts, and it was anticipated
that the ectopic expression of band 3 protein in fibroblasts
could be readily monitored. The expression of the anion
transporter protein from the SFCV-BIIIR provirus, in fact,
caused vacuolization of the infected fibroblasts. Recently
published data from studies using a neuronal homolog of
murine band 3 protein expressed in COS cells (36) showed
that ectopic anion transporter expression caused intracellu-
lar acidification. This was also seen when murine erythroid
band 3 protein was expressed in Xenopus oocytes (2). Thus,
under normal culture conditions, the anion transporter ex-
changes intracellular HC03- for extracellular Cl- in a
manner dependent on the bicarbonate and chloride content
of the medium. In fibroblasts infected with SFCV-BIIIR
viruses, vacuolization was presumably due to intracellular
acidification, since this phenotype could be abolished by
growing the cells in alkaline medium. An interpretation of
this is that the addition of extra bicarbonate to increase the
pH of the medium altered the anion exchange activity,
thereby relieving the vacuolization. This hypothesis is sup-
ported by the experiments with DIDS, which irreversibly
blocked band 3 protein anion exchange activity. When DIDS
was added to the culture medium, cellular vacuolization in
band 3 protein-containing fibroblasts was relieved. Effects of
intracellular acidification were probably relieved in SFCV-
BIIIR cells by sequestration of acidic groups in vacuoles,
though this has not been directly tested. The presence of
band 3 protein and the multiple, large vacuoles did not
appear to affect the growth rate of the cells. This band 3
protein-associated vacuolization has also been reported for
erythroblasts (68). In these experiments, erythroblasts were
infected with an AEV virus which harbors a defective
v-erbA; the cells were vacuolated when cultivated in me-
dium of the inappropriate pH or lacking DIDS, whereas this
phenotype was absent in pH-adjusted medium. Further-
more, the vacuolization in erythroblasts could be abolished
by expression of the normal v-erbA oncogene, which com-
pletely repressed band 3 protein gene expression.
The phenotype induced by the ectopic expression of band
3 protein activity at the plasma membrane of infected
fibroblasts provided a visual marker for the correct tran-
scription, translation, transport, and stability of sequences
transduced by SFCV-neo. Though the band 3 anion ex-
change protein is encoded by two polypeptides in avian
cells, we have shown that the expression of one of these
proteins is sufficient for the proper transport, plasma mem-
brane localization, and expression of anion exchange activ-
ity in SFCV-BIIIR-infected CEFs. We estimate that the
amount of band 3 protein expressed in these fibroblasts is
similar to the abundance of native band 3 in mature eryth-
rocytes (data not shown), judged by immunoprecipitation
experiments.
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